Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?
Ünal D, Eyice-Karabacak D, Kutlu A, Demir S, Tüzer C, Arslan AF, Işık SR, Gelincik A
Allergy · 12 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2023-08-07 · Allergy · vol. 78 · número 12 · págs. 3241–3251
- Editorial
- Wiley
- Citado
- 17 citas · más que el 90% de estudios similares · 2.4× el promedio de su campo
- Referencias
- 61 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Food Allergy and Anaphylaxis Research · Allergic Rhinitis and Sensitization · Mast cells and histamine
- Palabras clave
- Medicine, Allergy, Tick, Concomitant, Food allergy, Immunoglobulin E, Anaphylaxis, Adverse effect, Incidence (geometry), Internal medicine, Oral immunotherapy, Gastroenterology, Antibody, Immunology, Veterinary medicine
- MeSH
- animals, cattle, sheep, humans, food hypersensitivity, galactose, immunoglobulin e, allergens, immunotherapy, meat, adult, tick bites, biomarkers, red meat
8 autores
- Derya Ünal🇹🇷Istanbul University
- D. Eyice‐Karabacak🇹🇷Istanbul University
- Ali KUTLU🇹🇷Ordu University
- Semra Demir🇹🇷Istanbul University
- Can Tüzer🇹🇷Istanbul University
- Ahmet Arslan🇹🇷Istanbul University
- Sacide Rana Işık🇹🇷Yedikule Teaching Hospital
- Asli Akkor Gelincik🇹🇷 · autor de correspondenciaIstanbul University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Oral immunotherapy (OIT) is a promising treatment for food allergies. Our aim was to establish the long-term safety and efficacy of a novel red meat (RM) OIT in galactose-alpha-1,3-galactose (alpha-gal) allergy in adults.
Methods
Out of 20 patients with confirmed RM allergy, five (41.66%) underwent an early OIT, seven (58.33%) underwent a delayed protocol and eight patients who were not desensitized formed the patient control group. 15 and 27 day RM OIT for early-onset and delayed-onset alpha-gal allergy were administered, respectively. Desensitized patients were recommended to continue eating at least 100 g RM every day for 6 months and every other day in the following 6 months. After a year, the consumption was recommended 2/3 times in a week. Patients were followed up with skin tests with commercial beef and lamb extracts, fresh raw/cooked beef and lamb and cetuximab and also with serum alpha-gal specific Immunoglobulin-E (sIgE) in the first and fifth years.
Results
All patients who underwent OIT became tolerant to RM. During the 5 year follow-up, the median alpha-gal sIgE concentration gradually decreased in nine patients who consumed RM uneventfully while remained unchanged in the control group (p = .016). In two patients, rare tick bites acted as inducers of hypersensitivity reactions with concomitant elevation of alpha-gal sIgE concentrations whereas one patient with low follow-up alpha-gal sIgE concentrations consumed RM uneventfully after frequent tick bites.
Conclusions
Our study showed the long-term safety and efficacy of alpha-gal OIT. Additionally, alpha-gal sIgE seems to be a potential biomarker to monitor OIT.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.